CSF tau protein and FDG PET in patients with aging-associated cognitive decline and Alzheimer’s disease by Hunt, Aoife et al.
© 2006 Dove Medical Press Limited.   All rights reserved
Neuropsychiatric Disease and Treatment 2006:2(2) 207–212 207
ORIGINAL RESEARCH
CSF tau protein and FDG PET in patients with 
aging-associated cognitive decline and Alzheimer’s 
disease
Aoife Hunt
Peter Schönknecht
Markus Henze
Pablo Toro
Uwe Haberkorn
Johannes Schröder
Memory Clinic, Section of Geriatric 
Psychiatry, University Hospital 
Heidelberg, Ruprecht-Karls-University, 
Germany
Correspondence: Johannes Schröder
Section for Geriatric Psychiatry, 
Ruprecht-Karls-University Heidelberg, 
Voss-Str.4, D-69115 Heidelberg, Germany
Tel +49 6221 564403
Fax +49 6221 565327
Email Johannes_Schroeder@med.uni-
heidelberg.de
Introduction: In Alzheimer’s disease (AD), accelerated neuroﬁ  brillary tangle formation 
occurs which is associated with increased tau protein release into the cerebrospinal ﬂ  uid (CSF). 
Recent studies found signiﬁ  cantly increased CSF tau already in patients at risk of developing 
AD, indicating its potential as a biochemical marker of AD. Cerebral glucose metabolism is 
reduced in frontotemporoparietal and cingulate cortices in patients with mild AD. However, 
few studies have investigated CSF tau protein and cerebral glucose metabolism changes in 
patients at risk to develop AD.
Methods: 48 patients with AD, 88 patients with aging-associated cognitive decline 
(AACD), and 39 healthy controls were included. In all participants, CSF levels of tau were 
determined by ELISA at baseline and compared between the diagnostic groups. 14 AACD 
patients and 14 controls underwent 18F-ﬂ  uorodeoxyglucose positron emission tomography 
(FDG PET).
Results: AD patients showed the highest CSF tau levels compared with AACD patients and 
controls. AACD patients had signiﬁ  cantly higher tau levels than the controls but lower than the 
AD patients. AACD patients were characterized by reduced glucose metabolism in bilateral 
middle temporal cortex, left posterior cingulate cortex, right angular gyrus, and right precuneus 
compared with controls.
Conclusion: In conclusion, our ﬁ  ndings reﬂ  ect and conﬁ  rm the clinical judgment of an incipi-
ent neurodegenerative disorder in a considerable portion of AACD patients. In patients with 
AACD, CSF tau levels and cerebral glucose metabolism show an altered pattern comparable 
with that found in AD and thus may facilitate early diagnosis.
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Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized 
by histopathological changes such as neuroﬁ  brillary tangle formation and amyloid 
plaque deposition in susceptible brain regions. Epidemiological studies showed 
that before the onset of dementia a subtle cognitive impairment occurs which can 
be stable over many years (Schröder et al 1998; Elias et al 2000) but longitudinally 
leads to AD with an annual conversion rate of around 15% (De Carli 2003). Since 
treatment and monitoring of the disease requires an early diagnosis, various potential 
preclinical syndromes such as mild cognitive impairment (MCI) (Petersen et al 2001) 
have been proposed. The widely accepted amnestic MCI refers to minor, chieﬂ  y 
mnestic cognitive deﬁ  cits in elderly individuals which exceed those of the normal 
physiological aging processes, but which are not severe enough to fulﬁ  l a clinical 
diagnosis of dementia. However, in a recent follow-up study, MCI has been found Neuropsychiatric Disease and Treatment 2006:2(2) 208
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to be rather unstable compared with other concepts such as 
aging-associated cognitive decline (AACD), which refers 
also to non-mnestic deﬁ  cits (Levy et al 1994; Ritchie et al 
2001; Schönknecht et al 2005).
Since a long period of mild cognitive changes before 
the onset of dementia has to be considered, neurobiological 
markers to deﬁ  ne onset and course of AD are warranted. 
Cerebrospinal ﬂ  uid (CSF) tau protein, which is related to 
an increased neuroﬁ  brillary tangle formation in the brain, 
was found to be signiﬁ  cantly increased in AD patients com-
pared with controls (Schönknecht et al 2003a). Other studies 
demonstrated that a considerable proportion of AD patients 
do not show increased tau levels (Schönknecht et al 2003b). 
Moreover, increased tau protein release also occurred after 
acute cerebrovascular damage or other than AD-speciﬁ  c 
neurodegenerative pathology such as Creutzfeldt-Jakob 
disease (CJD) (Buerger et al 2006), making inconclusive 
the use of this marker to identify incipient AD cases among 
patients at risk of developing AD (for review see Blennow 
and Hampel 2003).
Therefore, brain imaging might provide an alternative 
diagnostic measure to reveal potential preclinical changes 
of AD. Previous magnetic resonance imaging (MRI) studies 
revealed that atrophic changes in AD patients primarily strike 
substructures of the medial temporal lobe but proceed to 
temporoparietal association cortices with disease progression 
(Pantel et al 1997). Using structural MRI, medial temporal 
lobe atrophy was conﬁ  rmed both in patients with incipient 
AD and in subjects at risk for developing dementia (Pantel 
et al 2003). In comparison with controls, AD was charac-
terized by a rapid decline of hippocampal volumes while 
only a moderate decrease of whole brain volumes occurred, 
indicating that hippocampal atrophy was not merely a func-
tion of generalized brain atrophy (Pantel et al 2002). In the 
cited study, progression of hippocampal atrophy but not of 
whole brain atrophy was signiﬁ  cantly correlated with clini-
cal deterioration.
Cognitive deﬁ  cits in AD and AACD are hypothesized to 
be related to reduced cerebral glucose uptake. Furthermore, 
various neuropsychological deﬁ  cits have been shown to be 
correlated with distinct patterns of cerebral glucose uptake 
(Schröder et al 2001; Desgranges et al 2002). Recent 
studies have proven 18F-fluorodeoxyglucose positron 
emission tomography (FDG PET) to be a sensitive tool 
to distinguish manifest but also incipient AD from con-
trols (de Leon et al 2001; Schröder et al 2001; Silverman 
et al 2001). A large European multi-center study of 
395 patients with AD and 110 controls showed reduction 
of temporoparietal, frontal and posterior cingulate cortical 
glucose metabolism in AD compared with controls 
(Herholz et al 2002). Drzezga et al (2003) found in a 
study of 22 MCI patients reduced glucose metabolism in 
temporoparietal and cingulate cortices which extends at 
follow-up to lateral prefrontal areas in those who convert 
to AD. However, studies that investigated FDG PET in 
patients with AACD are warranted. In the present study, 
we measured CSF tau in a large group of AD patients, 
AACD patients, and controls, and investigated cerebral 
FDG PET in a subgroup.
Methods
Patients
175 patients and controls recruited consecutively through 
the Section for Geriatric Psychiatry at University Hospital 
Heidelberg participated in the study. 48 patients diagnosed 
with probable Alzheimer’s disease (NINCDSADRDA) 
criteria: McKhann et al 1984) and 88 patients with mild 
cognitive impairment who met the AACD criteria were 
included. AACD was diagnosed according to the criteria 
of the International Psychogeriatric Association work-
ing party including: (1) subjective impairment reported 
by the individual or a reliable informant; (2) objective 
impairment – difﬁ  culties in any of the following cognitive 
domains as indicated by a neuropsychological test perfor-
mance of at least one standard deviation below age and 
education norms: memory and learning, attention and con-
centration, abstract thinking (problem solving, abstraction), 
language, and visuospatial functioning; and (3) exclusion 
criteria: none of the abnormalities listed above is of a 
sufﬁ  cient degree for a diagnosis of dementia or can be 
attributed to a clinically signiﬁ  cant psychiatric disorder 
(in particular depression, substance abuse, psychosis). 
Furthermore, there should be no objective evidence from 
physical and neurological examination or laboratory tests 
and no history of cerebral disease, damage, or dysfunction, 
or of systemic physical disorder known to cause cognitive 
dysfunction (Schönknecht et al 2005).
Clinical diagnosis was based on all relevant infor-
mation including history, clinical examination, blood 
parameters (full blood count, blood chemistry, erythrocyte 
sedimentation rate, thyroid function tests), neuropsycho-
logical, and neuroradiological ﬁ  ndings. Patients were 
excluded if they had evidence of stroke or other neurologi-
cal disorder, severe uncontrolled diabetes, or uncontrolled 
hypertension. The modiﬁ  ed Hachinski ischemic score 
of patients and controls was less than three (Loeb and Neuropsychiatric Disease and Treatment 2006:2(2) 209
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Gandolfo 1983). Severity of dementia was rated on the 
Mini Mental State Examination Scale (MMSE) (Folstein 
et al 1975).
CSF tau protein acquisition
At baseline, in all patients lumbar puncture was performed 
at a ﬁ  xed time of the day, between 10.00 and 12.00 hours, as 
part of the routine diagnostic procedure to exclude inﬂ  am-
matory disease. The resultant CSF samples were immedi-
ately aliquoted into nonabsorbent tubes, frozen at −80°C, 
and stored in polypropylene tubes until examination. Tau 
levels were determined using the Innogenetics INNOTEST-
hTau-Ag-kit3 (Vandermeeren et al 1993). Investigators were 
blinded to diagnosis prior to the measurement of tau. The 
CSF tau control group consisted of 39 individuals without 
cognitive impairment, psychiatric or neurological disorder 
from whom CSF samples were obtained during spinal anes-
thesia at the Department of Anesthesia, University Hospital 
Heidelberg.
FDG PET study protocol
In 14 of AACD patients and 14 controls, a cerebral 
FDG PET was performed. The FDG PET control group 
comprised subjects without cognitive disorder who had 
presented to the memory clinic requesting neuropsycho-
logical work-up. The PET protocol has been described 
previously (Schönknecht et al 2003c). PET was performed 
after at least a 6-hour fast. Before injection of 225 MBq 
18F-2-ﬂ  uoro-2-deoxy-D-glucose, blood glucose levels were 
determined and were shown to be below 110 mg/dL in all 
patients. From 15 minutes before injection until 45 minutes 
after, patients rested in a quiet room with dimmed light. 
Patients were told to keep their eyes closed but their ears 
were left unplugged, in order to avoid frontal activation as 
reported in total sensory deprivation studies. Then, emis-
sion scans over 20 minutes were acquired, followed by the 
transmission scans over 5 minutes using three 68 Ge line 
sources. Measurements were obtained with a whole-body 
PET system (ECAT EXACT HR+, CTI, Knoxville, TN, 
USA), covering 155 mm in the axial ﬁ  eld of view (63 trans-
versal slices, thickness of each slice 2.4 mm). The scanner 
consists of four rings each with 72 bismuth germanate 
detector blocks. Data were acquired in the more sensitive 
3D mode without inter-slice tungsten septa, which was 
found to be equivalent to the 2D mode for quantiﬁ  cation of 
radioactivities used in the clinical setting. The matrix size 
was 128 × 128 pixels. In 3D mode, the transaxial resolution 
is between 4.1 and 4.8 mm. Iterative image reconstruction 
used the ordered subsets-expectation maximisation 
(OSEM) algorithm, implemented in the ECAT V7.1 
software (Siemens Medical Systems Inc., Knoxville, 
TN, USA).
Image analysis and statistics
Basic image processing was done by MEDx 3.0 (Sensor Sys-
tems, Inc.) including statistical parametric mapping (SPM) 
routines (Wellcome Department of Cognitive Neurology, 
London; Friston et al 1995) on a Silicon Graphics station. All 
data were spatially normalized by afﬁ  ne 12-parameter trans-
formation to standard stereotactic space using the Montreal 
Neurological Institute (MNI) template. Normalized images 
were represented on a 78 × 76 × 85 matrix and smoothed 
by a Gaussian ﬁ  lter of 12 mm full width at half maximum 
(FWHM). PET data were analyzed at a voxel level, where a t 
test is performed at each voxel and a map of the correspond-
ing Z scores is pictured. The basic statistical model for the 
analyses was proportional scaling (p   0.001, uncorrected 
for multiple comparisons). The cerebral structures were 
identiﬁ  ed by their coordinates according to the Talairach 
atlas (Talairach and Tournoux 1988). Data were derived from 
the MNI template and were transformed to Talairach atlas 
coordinates using the appropriate algorithms (http://www.
mrc-cbu.cam.ac.uk )
Statistical analyses
For data analysis, Pearson correlation coefﬁ  cients, and analy-
ses of variance with Duncan’s post hoc test were calculated. 
The study was approved by the Ethics Committee of the 
University of Heidelberg.
Results
Means and standard deviations of the clinical variables are 
given in Table 1. According to the results of a Duncan’s test 
at the 5% level, CSF tau protein concentrations were high-
est in the AD patients and differed signiﬁ  cantly from those 
measured in patients with AACD. In the AD patients and the 
AACD patients, CSF tau protein levels were signiﬁ  cantly 
higher than in controls. As expected, the lowest MMSE 
scores were observed in the AD patients followed by the 
AACD patients, and both groups had signiﬁ  cantly lower 
scores than controls. AD patients were signiﬁ  cantly older 
than both AACD and controls.
According to the results of a discriminant function 
analysis, tau levels discriminated between AD patients and 
controls with a sensitivity of 68% and a speciﬁ  city of 97% 
yielding a correct reclassiﬁ  cation rate of 73%.Neuropsychiatric Disease and Treatment 2006:2(2) 210
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AACD patients who underwent FDG PET scanning at 
resting state at baseline had a signiﬁ  cantly different pattern 
of cerebral glucose metabolism than the controls (Table 2). 
According to a SPM analysis in the AACD patients, a reduced 
baseline glucose metabolism occurred in the right precuneus, 
the right angular gyrus, the bilateral middle temporal gyri, 
and the left posterior cingulate cortex compared with controls 
(Figure 1).
Moreover, the AACD patients who underwent FDG PET 
scanning could be characterized by increased CSF tau protein 
levels (451 ± 171 pg/ml) that were similar to those found in 
the whole group of AACD patients.
Discussion
The study revealed two major ﬁ  ndings. Firstly, patients with 
AD showed signiﬁ  cantly increased CSF tau protein levels 
compared with AACD patients and controls. Secondly, 
AACD patients who underwent FDG PET scanning were 
characterized by signiﬁ  cantly decreased temporal and cin-
gulate cortex glucose metabolism similar to that found in 
patients with AD.
Our results confirm previous studies demonstrating 
increased total tau levels in AD patients compared with con-
trols without cognitive deﬁ  cits (Schönknecht et al 2004). The 
ﬁ  nding of signiﬁ  cantly increased CSF tau protein baseline 
levels in AACD patients is in accordance with recent studies 
on CSF tau protein in MCI patients (Andreasen et al 2003; 
Herukka et al 2005). This ﬁ  nding ﬁ  ts with the hypothesis of 
a long and neuropsychologically stable period of cognitive 
impairment before the onset of AD (Schönknecht et al 2005). 
However, tau levels in the AD group showed a high variability. 
In a previous study, we could demonstrate that AD patients 
with tau levels below the 25%-percentile of the distribution 
were characterized by a signiﬁ  cantly higher percentage of 
patients with presenile onset (Schönknecht et al 2003b).
Although all studies on CSF tau protein levels in AD 
agree with increased tau levels in AD compared with healthy 
controls, potential confounding factors have to be discussed. 
Since neuropsychiatric symptoms such as depressive symptoms 
and agitation are frequent in AD, one has to take into account 
potential psychotropic medication effects on tau protein release. 
In the past, medication effects were mainly investigated for beta 
amyloid 1-40 and 1-42 levels (Schröder et al 1997). However, 
recently we were able to exclude a correlation of CSF total 
tau levels, and dosage and type of psychotropic medication in 
patients with AD (Schönknecht et al 2003b).
Even if we could exclude vascular dementia (VaD) 
in the patients enrolled in our study, it seems pertinent to 
question the feasibility of separating AD from other demen-
tias. In accordance with some (Arai et al 1998) but not all 
previous studies (Skoog et al 1995; Andreasen et al 1998; 
Table 1 Clinical characteristics of patients and controls (n = 175) according to a Duncan’s test at the 5% level
Controls AACD AD Duncan’s test
a b c (5%)
Patients 39 88 48
Age at baseline (years) 57.9 ± 15.1 66.9 ± 11.5 73.5 ± 8.8 c   b   a
MMSE score at baseline 29.3 ± 0.7 26.7 ± 2.0 8.5 ± 2.9 c   b   a
CSF tau at baseline (pg/ml) 223.8 ± 97.3 395.0 ± 223.8 646.2 ± 324.4 c   b   a
Abbreviations: AACD, aging-associated cognitive decline;   AD, Alzheimer’s disease; CSF, cerebrospinal ﬂ  uid; MMSE, Mini Mental State Examination.
Table 2 Reduced cerebral glucose metabolism in AACD 
patients compared with controls at baseline
Region BA x1 y1 z1 Z score
R precuneus 7 6 −62 36 3.6
R angular gyrus 39 36 −62 40 3.5
R middle temporal gyrus 22 64 −34 0 3.3
L middle temporal gyrus 21 −58 −24 −8 3.2
R precuneus 7 2 −78 40 3.1
L cingulate gyrus 31 −2 −58 28 3.0
R middle temporal gyrus 39 46 −68 24 2.9
R angular gyrus 39 48 −66 32 2.8
1x, y, z:   Talairach coordinates of peaks.
Abbreviation: BA, Brodmann area.
Figure 1 Spots indicating reduced cerebral glucose metabolism in aging-associated 
cognitive decline patients compared with controls.Neuropsychiatric Disease and Treatment 2006:2(2) 211
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Tapiola et al 1998) we found previously signiﬁ  cantly 
elevated tau levels in AD compared with VaD (Schönknecht 
et al 2003b). Discrepancies between studies may be 
explained by elevated tau levels in some of the investigated 
VaD patients following an acute damage to cerebral tissue 
induced by an ischemic event. The temporal relationship 
between an ischemic episode and the CSF examina-
tion could thus explain part of the variance of tau levels 
observed in VaD patients. This assumption is in line with 
the ﬁ  nding by Arai et al (1998) who observed tau levels 
in patients with acute cerebral infarction to be increased 
2–3 weeks after the event, but to normalize several 
months later.
From the variability of tau levels in the AD patients it 
can be assumed that raised CSF tau supports the diagnosis 
of AD but normal values do not exclude it. Therefore, 
neuroimaging might provide an alternative method to 
distinguish potential preclinical stages of AD among 
AACD patients (Chetelat et al 2003). By using FDG 
PET as a functional neuroimaging method for reﬂ  ecting 
reduced cerebral glucose uptake, Herholz et al (2002) 
found bilaterally reduced temporal glucose metabolism 
in patients with incipient AD compared with controls. 
Nestor et al (2003) demonstrated in patients with mild 
AD reduced glucose metabolism in posterior cingulate 
cortex but also in the hippocampus. Moreover, functional 
imaging studies demonstrate the role of precuneus and 
cingulate cortex in memory function (Cabeza and Nyberg 
2000). Accordingly, in our study AACD patients showed 
reduced glucose metabolism compared with controls in 
right precuneus, right angular gyrus, bilateral middle tem-
poral gyri, and left posterior cingulate gyrus. Further PET 
studies found the respective brain regions to be involved 
in manifest AD (Herholz et al 2002; Nestor et al 2003). 
Reduction of glucose metabolism in susceptible brain 
regions parallels the ﬁ  nding of early increased tau levels 
and suggests AACD as a pre-state of AD, conﬁ  rming the 
ﬁ  ndings of structural studies of reduced hippocampal 
volume in AACD (Pantel et al 2003) as well as ﬁ  ndings 
of previous PET studies of reduced glucose metabolism 
in MCI patients who later convert to AD (Nestor et al 
2003).
In conclusion, our ﬁ  ndings reﬂ  ect and conﬁ  rm the 
clinical judgement of an incipient neurodegenerative dis-
order in a considerable portion of AACD patients. CSF 
tau levels and cerebral glucose metabolism distinguish 
controls from AACD and thus may facilitate early diag-
nosis of AD.
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